Technology: tools or toys, is it economically feasible with current reimbursement? The case in favor.
Tattersall
J
J
Sheffield Kidney Institute, Sheffield, UK. Jamestattersall@compuserve.com
D001769:Blood; D001810:Blood Volume; D001831:Body Temperature; D003363:Cost Control; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D004867:Equipment Design; D017583:Hemodiafiltration; D006440:Hemofiltration; D006801:Humans; D007349:Insurance, Health, Reimbursement / Q000191:economics* / Q000706:statistics & numerical data; D007676:Kidney Failure, Chronic / Q000191:economics* / Q000401:mortality / Q000628:therapy; D007688:Kidneys, Artificial / Q000191:economics; D008991:Monitoring, Physiologic; D011788:Quality of Life; D006435:Renal Dialysis / Q000191:economics* / Q000295:instrumentation; D015996:Survival Rate; D013675:Technology, High-Cost / Q000191:economics*; D016896:Treatment Outcome; D006113:United Kingdom; D014481:United States